Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $31.97 Million Holdings in Pfizer Inc. (NYSE:PFE)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,204,972 shares of the biopharmaceutical company’s stock after selling 28,613 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Pfizer were worth $31,968,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer during the 4th quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.5 %

PFE stock opened at $26.18 on Thursday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market cap of $148.35 billion, a P/E ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61. The business’s 50 day moving average is $26.19 and its 200-day moving average is $27.08. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.